Person: UYSAL, ÖMER
7 results
Search Results
Now showing 1 - 7 of 7
Publication Metadata only The effects of human amniotic membrane on silicone related capsule formation in rats.(2020-05-19T00:00:00Z) Akyürek, M; Orhan, E; Aydın, MŞ; Uysal, ÖMER; Karşıdağ, S; UYSAL, ÖMERPublication Metadata only Association between polymorphisms in HLA-A, HLA-B, HLA-DR, and DQ genes from gastric cancer and duodenal ulcer patients and cagL among cagA-positive Helicobacter pylori strains: The first study in a Turkish population.(2020-03-13T00:00:00Z) Dınc, HO; Kocak, BT; Saribas, S; Demiryas, S; Yilmaz, E; Uysal, ÖMER; Kepil, N; Demirci, M; Akkus, S; Gülergün, R; Gareayaghi, N; Dağdeviren, HE; Ozbey, D; Dağ, HH; Tokman, HB; Tasci, I; Kocazeybek, B; UYSAL, ÖMER; DİNÇ, HARİKA ÖYKÜPublication Open Access Cytokine Polymorphism and HLA Genotyping in Patients with Temporal Lobe Epilepsy Related to Hippocampal Sclerosis.(2017-12-01) ALTINTAŞ, A; ÖZKARA, Ç; Sohtaoğlu, Sevindik; UZAN, M; Kekik, Çinar; Uysal, ÖMER; Savran, Oğuz; UYSAL, ÖMERObjective: Hippocampal sclerosis (HS) is the most common pathological substrate associated with mesial temporal lobe epilepsy (MTLE), where inflammatory processes are known to play an increasingly important role in the pathogenesis. To further investigate the role of the immune system, both cytokine gene polymorphisms and human leukocyte antigen (HLA) genotyping in patients with MTLE-HS were investigated. Methods: The DNA samples of 100 patients with MTLE-HS and 201 healthy individuals were genotyped for cytokines (IL-6,IL-10, TNF-α, TGF-β1 and IFN-γ) and HLA using polymerase chain reaction (PCR)-SSP and SSO methods. The results were statistically analyzed in patient and healthy control groups and then according to the presence of febrile seizures (FS) in the patient group. Results: Analysis of cytokine genotyping did not reveal any significant difference between patients with MTLE-HS and controls and patients with or without FS. However, the HLA DRB1*13 allele was found to be more frequent in the patient population after Bonferroni correction. Conclusion: This study suggests the possible role of HLA in the pathogenesis of MTLE-HS, although it failed to show any relationship with the cytokine system. However, data regarding the role of HLA are still lacking, and further studies are necessary to verify our results.Publication Metadata only Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease.(2015-07-01) Ince, AT; Gangarapu, V; Baysal, B; Kayar, Y; Şenturk, H; Gök, Ö; Uysal, ÖMER; İNCE, ALİ TÜZÜN; UYSAL, ÖMER; ŞENTÜRK, HAKANObjectiveRecent studies have suggested that endotoxin-induced cytokines play an important role in nonalcoholic fatty liver disease (NAFLD). Rifaximin is a nonabsorbable antibiotic that might act on Gram-negative bacteria, thereby inhibiting endotoxin proinflammatory cytokine production in patients with NAFLD. Our aim was to investigate the efficacy of rifaximin on NAFLD.MethodsForty-two patients with biopsy-proven NAFLD [15 steatosis, 27 nonalcoholic steatohepatitis (NASH)] were included in this prospective, open-label, observational cohort study. BMI and serum aspartate aminotransferase, alanine aminotransferase (ALT), gamma glutamyl transferase, lipid profile, ferritin, C-reactive protein, glucose, insulin, homeostatic model assessment as well as endotoxin, serum Toll-like receptor 4 (TlR4), interleukin-1 (IL-1), IL-6, IL-10, IL-12, and tumor necrosis factor- (TNF-) levels were measured before and after a 28-day administration of rifaximin (1200mg/daily). Results were analyzed using nonparametric Wilcoxon signed-rank tests.ResultsA mild reduction in the mean BMI (32.36.9 vs. 31.9 +/- 6.8, P=0.02) and a significant reduction in the endotoxin (0.9 +/- 0.34 vs. 0.8 +/- 0.13, P=0.03) and IL-10 (4.08 +/- 0.9 vs. 3.73 +/- 0.7, P=0.006) levels in the NASH group were noted. A significant reduction was observed in serum aspartate aminotransferase (50.4 +/- 39 vs. 33 +/- 14, P=0.01), ALT (72 +/- 48 vs. 45.2 +/- 26.3, P=0.0001), gamma glutamyl transferase (52 +/- 33 vs. 41.2 +/- 21.1, P=0.02), LDL (137 +/- 34 vs. 127 +/- 27.5, P=0.03), and ferritin (142 +/- 214 vs. 89.3 +/- 123, P=0.0001) in the NASH group, but only in ALT (50.4 +/- 26 vs. 35.5 +/- 23.25, P=0.01), and ferritin (73.6 +/- 83 vs. 55 +/- 76, P=0.004) levels decreased significantly in the steatosis group. Treatment with rifaximin did not exert a significant effect on serum levels of TLR-4, IL-1, IL-6, IL-12, or TNF- in either group.ConclusionIn NAFLD and especially in NASH, short-term administration of rifaximin appears to be safe and effective.Publication Metadata only Predictors of obturator functioning and satisfaction in Turkish patients using an obturator prosthesis after maxillectomy.(2018-03-01) Ozdemir-Karatas, M; Balik, A; Evlioglu, G; Uysal, ÖMER; Peker, K; UYSAL, ÖMERPublication Open Access Psychiatric symptoms, challenging behaviour and utilization of psychiatric services among adults with intellectual disabilities in Turkey.(2020-03-24T00:00:00Z) Gormez, A; Kurtulmus, A; Ince, Z; Torun, P; Uysal, ÖMER; Cıtak, S; UYSAL, ÖMERBackground: The aim of this study was to investigate the prevalence of and the factors associated with psychiatric symptoms (PS) and challenging behaviour (CB) in adults with intellectual disabilities, and the utilization of psychiatric services in Turkey. Method: Psychiatric Assessment Schedule for Adults with Developmental Disorders Checklist-Revised was used for PS and a structured form for other variables in 771 participants. Results: Of the participants, 50.1% had PS and 36.4% presented with CB. Multivariate analysis revealed that a higher level of needs, better verbal ability, residential living, incontinence and CB, and lifetime suicidal ideation/attempt were independently associated with PS. For CB, it emerged as male carer, PS, lifetime suicidal attempt/ideation, lower level of verbal ability and autism spectrum disorder. Barriers were experienced by 64.7% of participants within the previous year. Conclusions: Psychiatric symptoms and CB seem to be problems for a significant proportion of adults with intellectual disabilities in Turkey, and there are certain barriers to psychiatric services.Publication Metadata only Neopterin and soluble CD14 levels as indicators of immune activation in cases with low anti-HCV reactivity and true HCV infection(2017-01-01) Habip, Z.; Sohrabi, P.; Saribas, S.; Caliskan, R.; Demirci, M.; Karakullukcu, A.; Atalik, K.; Yuksel, P.; Uysal, ÖMER; Kosan, E.; Tokman, H. Bahar; Kocazeybek, B.; YÜKSEL MAYDA, PELİN; UYSAL, ÖMERNeopterin and soluble CD14 (sCD14) are detected at high levels in hepatitis C virus (HCV) infections. We aimed to evaluate the role of these plasma immune activation biomarkers, for the indirect assessment of immune activation status of patients with low anti-HCV reactivity and a HCV infection. Low anti-HCV reactivity group (LRG, n: 70), true positive HCV infection group (THG, 30) and healthy control group (HCG, 30) were analyzed in this study. We have used ELISA, HCV RIBA/LIA and HCV-RNA methods. Mean neopterin levels were significantly lower in LRG than THG (p 0.05). Mean sCD14 were significantly higher in LRG than THG and HCG (p <0.05, p <0.001). Values of 3.95 mu g/ml and 5.36 nmol/l for sCD14 and neopterin resulted in the maximum area under the receiver operating characteristic curves (ROC), which were 0.859 (95% CI, 0.745 to 0.935; <0.0001) and 0.788 (95% CI, 0.663 to 0.883; <0.0001), respectively. These cut-offs corresponded to a sensitivity of 73.3% and a specificity of 73.3% for neopterin and of 100% and 76.7% for sCD14. Our results suggest that a specific immunoactivation might be caused by true positive HCV infection. Due to the significant results sCD14 in LRG might be non-specifically affected by some underlying atypical immunohematological pathologies. Only neopterin might be used to exclude low anti-HCV reactivity from a true HCV infection. The use of neopterin but not sCD14 in combination with fourth-generation EIA/CMIA combo tests will be useful when nucleic acid tests are not available for screening blood donors at blood banks.